Long-term immune response accompanies clinical outcomes in severe asthmatics treated with anti-IL-5/IL-5R biologics

Article Allergy

Long-Term Real-World Outcomes of Mepolizumab and Benralizumab Among Biologic-Naive Patients With Severe Eosinophilic Asthma: Experience of 3 Years' Therapy

Fred Fyles et al.

Summary: This study demonstrates that benralizumab and mepolizumab can significantly improve OCS use, annual exacerbation rate, and asthma control in real-world cohorts of patients with severe eosinophilic asthma (SEA) for up to 36 months, providing insights into the long-term use of these medications for SEA.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2023)

Add to Collection

Article Respiratory System

Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity

Rania Dagher et al.

Summary: Benralizumab, a humanised monoclonal antibody, shows potent anti-eosinophilic activity through induction of eosinophil apoptosis and phagocytosis by macrophages. The mechanism involves NK cells, macrophage-derived TNF, and activation of Caspase-3/7 and cytochrome c. The afucosylation of benralizumab enhances its potency for these mechanisms.

EUROPEAN RESPIRATORY JOURNAL (2022)

Add to Collection

Article Allergy

Mepolizumab decreases tissue eosinophils while increasing type-2 cytokines in eosinophilic chronic rhinosinusitis

Sophie Walter et al.

Summary: This study demonstrates that Mepolizumab can effectively reduce eosinophil counts in sinonasal tissue of patients with eosinophilic chronic rhinosinusitis. However, it does not appear to have a significant effect on eosinophil degranulation. Additionally, the use of Mepolizumab leads to increased levels of type-2 cytokines in sinonasal tissue, suggesting a local inflammatory feedback loop.

CLINICAL AND EXPERIMENTAL ALLERGY (2022)

Add to Collection

Review Pharmacology & Pharmacy

Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets

Corrado Pelaia et al.

Summary: Interleukins (IL)-4 and -13 play a crucial role in type-2 asthma, and dupilumab acts as a dual receptor antagonist to effectively treat type-2 inflammation-related diseases.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Article Immunology

Benralizumab reduces eosinophils and inflammatory markers in patients with severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: A pilot real-life study.

Carlo Cavaliere et al.

Summary: This study found that treatment with benralizumab improved clinical symptoms and reduced mucosal inflammation in patients with severe CRSwNP and SEA. Additionally, INF-γ and VEGF may serve as potential biomarkers for treatment response.

IMMUNOLOGY LETTERS (2022)

Add to Collection

Article Allergy

Sputum TNF markers are increased in neutrophilic and severe asthma and are reduced by azithromycin treatment

Natalie M. Niessen et al.

Summary: This study investigated the association between TNF markers and clinical phenotypes of asthma, as well as the effect of azithromycin treatment on these markers. The results showed dysregulation of TNF markers in the airways related to important asthma phenotypes, with azithromycin treatment significantly reducing TNF levels in non-eosinophilic participants.

ALLERGY (2021)

Add to Collection

Review Respiratory System

A pragmatic guide to choosing biologic therapies in severe asthma

Joanne E. Kavanagh et al.

Summary: Biologics have become an important treatment option for severe asthma, targeting different inflammatory pathways to reduce exacerbations and corticosteroid requirements. Physicians should consider patients' clinical characteristics, biomarker levels, and personal preferences when selecting the most appropriate treatment approach.

BREATHE (2021)

Add to Collection

Article Allergy

Airway basophils are increased and activated in eosinophilic asthma

Y. Suzuki et al.

ALLERGY (2017)

Add to Collection

Review Cardiac & Cardiovascular Systems

Transforming growth factor β and severe asthma: A perfect storm

Mazen Al-Alawi et al.

RESPIRATORY MEDICINE (2014)

Add to Collection

Long-term immune response accompanies clinical outcomes in severe asthmatics treated with anti-IL-5/IL-5R biologics

Related references

Export Citation

Share Paper